Emerging Treatments in Geographic Atrophy: Reason for Hope?

This session, which was included as part of the 2023 Ophthalmology 360 Summit Series, will review the quality-of-life impact of geographic atrophy (GA) and examine current and emerging treatment approaches, including complement inhibitors and other pathways, such as neuroprotective agents and gene therapy. Discussion will include the rationale for various treatment approaches in GA and examine the safety and efficacy data from key clinical trials.

Upon completion of the educational activity, participants should be able to:

• Recognize the burden of GA secondary to age-related macular degeneration and its negative impact on quality of life
• Evaluate the latest efficacy and safety data from clinical trials of complement system inhibitors
• Review current and emerging approaches for monitoring and treating GA

To obtain a certificate of completion, a score of 70% or better on the post-test is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your certificate. You must participate in the entire activity to receive credit. There is no fee to participate in this activity. If you have questions about this activity, please contact AKH Inc. at ketrea@akhcme.com